

The following is a summary of the principal features of the Class U Units (the “Units”) of the Healthcare Leaders Income ETF (the “Fund”). You can find more detailed information about the Fund in the prospectus. The prospectus is available on Harvest’s website at [www.harvestportfolios.com](http://www.harvestportfolios.com), or by contacting Harvest at [info@harvestportfolios.com](mailto:info@harvestportfolios.com), or by calling toll-free 1.866.998.8298.

FUND DETAILS			
<b>Inception Date:</b>	November 19, 2014*	<b>RSP Eligibility:</b>	RRSPs, RRIFFs, RESPs, DPSPs & TFSA
<b>Ticker Symbol:</b>	HHL.U	<b>DRIP:</b>	Eligible
<b>CUSIP:</b>	42227H200	<b>Portfolio Manager:</b>	Harvest Portfolios Group Inc.
<b>Currency:</b>	USD	<b>Management Expense Ratio (MER):</b>	Not Available
<b>Distributions:</b>	Monthly, \$0.0583 USD per unit	<b>Exchange:</b>	TSX

\*The Fund was formerly known as “Healthcare Leaders Income Fund” and was originally established as a closed-end investment trust under the laws of Ontario on November 19, 2014 and was listed on the TSX on December 18, 2014. The Fund converted from a closed-end fund into an exchange-traded fund on October 24, 2016.

**INVESTMENT OBJECTIVE**

The Fund’s investment objective is to provide Unitholders with: (i) the opportunity for capital appreciation; (ii) monthly cash distributions; and (iii) lower overall volatility of Portfolio returns than would otherwise be experienced by owning Equity Securities of the Healthcare Leaders directly. To achieve lower overall volatility of portfolio returns, the Fund will generally write covered call options on up to 33% of the portfolio securities. The level of covered call option writing may vary based on market volatility and other factors.

**INVESTMENTS OF THE FUND**

The charts below are intended to give you a snapshot of the Fund’s investments on May 31, 2017. The Fund’s investments will change.

		<u>Investment Mix</u>	
<b>Top 10 Positions</b>	<b>% of NAV</b>	<b>Industry</b>	<b>% of NAV</b>
Stryker Corporation	5.2	Pharmaceutical Issuers	48.5
Johnson & Johnson	5.1	Biotechnology Issuers	18.9
Quest Diagnostics	5.1	Healthcare Equipment Issuers	15.3
Medtronic PLC	5.1	Managed Healthcare Issuers	10.0
GlaxoSmithKline PLC ADR	5.1	Healthcare Distributor Issuers	5.1
Merck & Co., Inc.	5.0	Cash and other assets and liabilities	2.7
Anthem, Inc.	5.0	Options	(0.5)
Boston Scientific Corp.	5.0		
AbbVie Inc.	5.0		
Novartis AG ADR	5.0		
<b>Total % of Top 10 Investments</b>	<b>50.6</b>	<b>Total</b>	<b>100.0</b>

**RISK**

Harvest Portfolios Group Inc. has rated the volatility of this Fund as **medium**. This rating is based on how much the Fund’s returns have changed from year to year. It doesn’t tell you how volatile the Fund will be in the future. The rating can change over time. A fund with a low risk rating can still lose money.

Low	Low to medium	<b>Medium</b>	Medium to high	High
-----	---------------	---------------	----------------	------

For more information about the risk rating and specific risks that can affect the Fund’s returns, see the “Risk Ratings of the Harvest ETFs” section of the Fund’s prospectus.

**FUND EXPENSES**

You don’t pay these expenses directly. They affect you because they reduce the Fund’s returns.

<b>Management Expense Ratio (MER)</b>	<b>Annual Rate (as a % of the Fund’s value)</b>
<i>This is the total of the Fund’s management fee and operating expenses.</i>	Not Available
<b>Trading Expense Ratio (TER)</b>	Not Available
<i>These are the Fund’s trading costs.</i>	
<b>Fund Expenses</b>	Not Available
<i>The amount included for fund expenses is the amount arrived at by adding the MER and the TER.</i>	
The Fund’s expenses are made up of the management fee, operating expenses and trading costs. The Fund’s annual management fee is 0.85% of the Fund’s value. Because this class of Units is new, its operating expenses and trading costs are not yet available.	

**TRAILING COMMISSIONS**

There are no trailing commissions paid on Units of the Fund.

**OTHER FEES**

You may pay brokerage fees to your dealer when you purchase and sell Units of the Fund.

**STATEMENT OF RIGHTS**

Under securities law in some provinces and territories, you have: (a) the right to cancel your purchase within 48 hours after you receive confirmation of the purchase, or (b) other rights and remedies if this document or the Fund’s prospectus contains a misrepresentation. You must act within the time limit set by the securities law in your province or territory. For more information, see the securities law of your province or territory or ask a lawyer.